ABSTRACT

3-FURANYL ANALOGS OF TOXOFLAVINE AS KINASE INHIBITORS

The present invention concerns the compounds of formula



(I)

the *N*-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein m represents an integer being 0 or 1; n represents an integer being 0, 1 or 2; R^1 represents C_{1-4}alkyl, C_{1-4}alkyl substituted with pyridinyl, phenyl, piperidinyl or piperidinyl substituted with C_{1-4}alkyloxycarbonyl; R^2 represents hydrogen or C_{1-4}alkyl; R^3 represents hydrogen or C_{1-4}alkyl; or R^2 and R^3 taken together with the carbon atom to which they are attached form cyclopentyl or piperidinyl wherein said cyclopentyl or piperidinyl each independently may optionally be substituted with one, or where possible, two or three substituents each independently selected from C_{1-4}alkyloxycarbonyl, phenylcarbonyl or –C(=NH)-NH_2; R^4 represents halo or C_{1-4}alkyloxy; R5 represents Het^2, C_{1-4}alkyl substituted with one or where possible more substituents being selected from hydroxy, halo, Het^3 or NR^6R^7, or C_{1-4}alkyloxy substituted with one or where possible more substituents being selected from Het^4 or –C(=O)-Het^4; R^6 and R^7 are each independently selected from hydrogen, C_{1-4}alkyl, Het^5 or C_{1-4}alkyl substituted with one or where possible more substituents being selected from hydroxy or Het^5; Het^2 represents piperazinyl; Het^3 represents a heterocycle selected from morpholinyl, pyrrolidinyl, piperidinyl, or piperazinyl wherein said monocyclic heterocycles each independently may optionally be substituted with one, or where possible two or three substituents each independently selected from C_{1-4}alkyl preferably methyl, aminosulfonyl, mono- or di(C_{1-4}alkyl)aminosulfonyl, hydroxyC_{1-4}alkyloxyC_{1-4}alkyl, C_{1-4}alkyloxyC_{1-4}alkyl or C_{1-4}alkyloxy; Het^4 represents a heterocycle selected from morpholinyl or piperazinyl wherein said monocyclic heterocycles each independently may optionally be substituted with one, or where possible two or three C_{1-4}alkyl substituents, preferably methyl; Het^5 represents a heterocycle selected from pyridinyl, pyrrolidinyl or piperidinyl wherein said monocyclic heterocycles each independently may optionally be substituted with one, or where possible two or three substituents each independently selected from aminosulfonyl, C_{1-4}alkyloxycarbonyl or mono- or di(C_{1-4}alkyl)aminosulfonyl.